Refractory Anaphylaxis: A New Entity for Severe Anaphylaxis

Guillaume Pouessel, Antoine Deschildre, Timothy E. Dribin, Ignacio J. Ansotegui, Victoria Cardona, R. Sharon Chinthrajah, Motohiro Ebisawa, Antonella Muraro, Graham Roberts, Hugh A. Sampson, Susan Waserman, Robert A. Wood, Margitta Worm, Paul J. Turner

Research output: Contribution to journalArticlepeer-review

Abstract

Anaphylaxis reactions lie on a spectrum of severity, ranging from relatively mild lower respiratory involvement (depending on the definition of anaphylaxis used) to more severe reactions that are refractory to initial treatment with epinephrine and may rarely cause death. A variety of grading scales exist to characterize severe reactions, but there is a lack of consensus about the optimal approach to define severity. More recently, a new entity called refractory anaphylaxis (RA) has emerged in the literature, characterized by the persistence of anaphylaxis despite initial epinephrine treatment. However, slightly different definitions have been proposed to date. In this Rostrum, we review these definitions as well as data relating to epidemiology, elicitors, risk factors, and management of RA. We propose a need to align the different definitions for RA, to improve epidemiological surveillance, advance our understanding of the pathophysiology of RA, and optimize management strategies to reduce morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)2043-2048
Number of pages6
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume11
Issue number7
DOIs
StatePublished - Jul 2023

Keywords

  • Anaphylaxis
  • Autoinjector
  • Emergency management
  • Epinephrine
  • Food allergy
  • Intensive care
  • Refractory

ASJC Scopus subject areas

  • Immunology and Allergy

Fingerprint

Dive into the research topics of 'Refractory Anaphylaxis: A New Entity for Severe Anaphylaxis'. Together they form a unique fingerprint.

Cite this